Increase in Chronic Diseases Despite Recovery from COVID-19 Pandemic

News by 2FIRSTS.ai
Dec.12.2023
Increase in Chronic Diseases Despite Recovery from COVID-19 Pandemic
According to Naver on December 7, after three years of the COVID-19 pandemic in South Korea, the proportion of chronic diseases such as overeating, obesity, and hypertension has increased.

According to a report by Naver on December 7th, despite the resumption of daily life and improvements in sports activities in South Korea after three years of the COVID-19 pandemic, there has been an increase in the prevalence of chronic diseases such as binge eating, obesity, and hypertension.

 

The "National Health and Nutrition Survey" is a survey conducted in accordance with the National Health Promotion Law, targeting individuals with an annual income of over 10,000 yuan. It covers over 250 public health indicators, including smoking, alcohol consumption, physical activity, nutrition, and chronic diseases.

 

The results indicate that although smoking rates have slightly declined in 2021, alcohol consumption rates have once again risen. Moreover, both men and women have shown an increase in participation in physical activities compared to last year.

 

The smoking rate among men last year was 36.6%, while it was 7.2% among women. The smoking rate for men remained the same as the previous year, while it decreased by 1.3 percentage points for women. Currently, the prevalence of smoking among men is 30%, while it is 5% among women, representing a decrease of 1.3 and 1.9 percentage points respectively compared to the previous year.

 

The smoking rate for vaping has seen a slight increase compared to last year, with 5.6% of men and 1.3% of women engaging in this activity. Additionally, there has been a growth in the use of heated tobacco products in the form of e-cigarettes (HNB products) as well. Among men, the usage rate has reached 9.2%, while for women it stands at 2.4%.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
An exclusive 2Firsts investigation found an unpublished FDA update on e-cigarette marketing authorizations that mirrors market speculation, suggesting Glas’s application may have cleared internal review, though no official confirmation has been issued.
Regulations
Dec.21
Perak to stop issuing new vape licences, aiming for a phased “zero sales” outcome after October
Perak to stop issuing new vape licences, aiming for a phased “zero sales” outcome after October
Perak executive councillor Datuk Sivanesan said the state government aims to progressively reach a “zero” level of vape sales no later than after October, noting vape operators were clearly informed in October 2025.
Jan.05 by 2FIRSTS.ai
Lao Shuts Down Nearly 300 Online Vape Stores in Joint Crackdown with WHO and Meta
Lao Shuts Down Nearly 300 Online Vape Stores in Joint Crackdown with WHO and Meta
In a coordinated effort with the World Health Organization (WHO) and Meta, the Lao Ministry of Health has taken 288 online e-cigarette stores with more than 759,599 members offline, reinforcing the country’s total ban on e-cigarettes under the National Tobacco Control Law.
Nov.20 by 2FIRSTS.ai
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
British American Tobacco (BAT) has announced plans to cut 51 jobs at its Groot-Bijgaarden facility in Belgium, disclosed during a special works council meeting.
Jan.15 by 2FIRSTS.ai
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives
PMI Extends Ferrari Partnership to 2026, Bringing ZYN Nicotine Pouches to F1
PMI Extends Ferrari Partnership to 2026, Bringing ZYN Nicotine Pouches to F1
Philip Morris International (PMI) has announced that it will extend its partnerships with Scuderia Ferrari HP and the Ferrari Challenge through the 2026 season and beyond, with its smoke-free nicotine pouch brand ZYN set to appear on Ferrari’s F1 livery for the first time from the 2025 Abu Dhabi Grand Prix. The company estimates that, as of June 30, 2025, more than 41 million adult consumers were using its smoke-free products worldwide.
Dec.04 by 2FIRSTS.ai